# The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study

> **NCT01217476** · PHASE3 · COMPLETED · sponsor: **Olympus Biotech Corporation** · enrollment: 207 (actual)

## Conditions studied

- Diabetic Foot Ulcer of Neuropathic Origin

## Interventions

- **DRUG:** Trafermin 0.01% spray

## Key facts

- **NCT ID:** NCT01217476
- **Lead sponsor:** Olympus Biotech Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-05
- **Final completion:** 2013-03
- **Target enrollment:** 207 (ACTUAL)
- **Last updated:** 2014-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01217476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01217476, "The TRAfermin in Neuropathic Diabetic Foot Ulcer Study - Northern Europe The TRANS-North Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01217476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*